Skip to main content

Can Tepezza treat eye bulging and double vision?

Medically reviewed by Carmen Pope, BPharm. Last updated on May 22, 2024.

Official answer

by Drugs.com

Yes, Tepezza is very good at treating eye bulging and double vision caused by thyroid eye disease with 8 out of 10 patients (82.9%) reporting a significant improvement in eye bulging, compared to placebo (an inactive treatment). Tepezza can also improve double vision (also called diplopia), visual ability, and physical appearance.

Tepezza reduced eye bulging by at least 2mm in the OPTIC study and also reduced eye swelling and how far the bulging eye protruded forward. It works by decreasing inflammation, preventing muscle and fat tissue remodeling, and preventing tissue expansion behind the eye. Patients also experienced less pain and redness from treatment. During clinical trials, improvements were noticed within six weeks.

References
  • TEPEZZA: Infusion Therapy for Thyroid Eye Disease. Infusion Associates. https://infusionassociates.com/infusion-therapy/tepezza-for-thyroid-eye-disease/#:~:text=What%20is%20TEPEZZA%3F,pain%20and%20redness%20from%20treatment.
  • Tepezza (teprotumumab) Updated 11/2021 https://www.drugs.com/tepezza.html
  • Tepezza (teprotumumab) Updated 02/2022. Horizon Therapeutics USA, Inc. https://www.drugs.com/pro/tepezza.html

Read next

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading

Tepezza (teprotumumab) is an inhibitor of insulin-like growth factor-1 receptor (IGF-1R) used to treat Thyroid Eye Disease (TED). It is a monoclonal antibody that blocks IGF-1R activation and signaling. Tepezza decreases eye bulging (proptosis) by decreasing inflammation, preventing muscle and fat tissue remodeling, and preventing tissue expansion behind the eye. Continue reading

After treatment, Tepezza has been shown in 24-week long clinical studies to reduce the eye bulging, double vision, eye pain, redness and swelling that may occur before treatment with TED. Some patients may have improvement in symptoms as early as 6 weeks. In addition, an improvement in vision (such as reading or watching TV) and in the patient’s appearance was also seen. Continue reading

Related medical questions

Drug information

Related support groups

Medical Disclaimer